Gynaecologists are the first clinicians whom the female patients with breast problems consult. The majority of breast lesions are benign. [1] Benign breast diseases account for up to 90% of breast clinic referrals. In fact, around 30% of women seek treatment for benign breast disorders at least once in their lifetime. Benign breast diseases are usually seen in the younger age group with incidence peaking in second and third decades thought to be largely hormone induced. Benign breast diseases are less common after menopause. [2]
Most of the women experience a lump with or without pain which inflicts fear of malignancy and gets the patient to the breast clinic, out of which 2/3rd are benign. The most common complaint in patients with benign breast diseases is breast lump or breast nodularity and breast pain. [2]
Most benign breast diseases are relatively minor aberrations of normal process of development, cyclical hormonal response, pregnancy and lactation related and involution that interact throughout a woman’s life. [3] Mastalgia may be cyclical and non-cyclical exacerbation of pain depending on its relation with menstrual cycle. It can cause interference in the daily life of females and it also raises fear and anxiety of breast carcinoma in them. [2]
To treat benign breast diseases agents like bromocriptine, tamoxifen, evening primrose oil (EPO) and danazol are used and were found to have lot of side effects due to their non selective estrogen blockade action and led to patient incompatibility. [4] Other agents like vitamins B6, E, diuretics, gamolenic acid, caffeine withdrawal have been used in the past but not found to be effective. [2] Likewise, creams, tablets, injectables were discarded from the study due to poor response. Hence, a new agent named ormeloxifene taken into account. Ormeloxifene is a class of medication which otherwise known as centchroman. [5]
Ormeloxifene belongs to a group of drugs known as the selective oestrogen receptor modulators which act on the oestrogen receptor. [6] It acts as weak oestrogen receptor agonist at bone and strong antagonist at uterus and breast. [7] .Ormeloxifene has shown promising results with minimal side effects. [2] Hence, the researcher makes an effort to investigate the extent to which ormeloxifene diminish the pain, reduces the size of the lump and decreases nodularity in patients suffering from the benign breast diseases.
The present study aimed to evaluate the efficacy of Ormeloxifene in reducing symptoms of mastalgia and nudularity in patients with benign breast diseases.
This prospective study was carried out in 100 patients having benign breast diseases in a tertiary care hospital of Ahmedabad. Patients with age groups from 18 years to 50 years were included in this study. Patients having complaints of Mastalgia bilateral /unilateral breast, Patients having complaints of Breast Lump bilateral /unilateral breast, Patients having benign breast disease confirmed by radiological investigations such as ultrasound or cytological study such as FNAC were included in the study after consented for the study. Patients with a discrete lump, which was suspicious of cancer after clinical, imaging and cytological examination were excluded from the study. Patients taking alternative treatment, lactating women, those planning a pregnancy or taking other oral contraceptive pills, Women suffering from polycystic ovarian disease, other hormonal abnormalities requiring additional investigations, and liver and kidney problems were also excluded from the study. All infective conditions and congenital anomalies were excluded. Patients who had previous operative history for benign breast condition were excluded.
Medical history and physical examination were performed for all the patients. Relevant investigations including USG and FNAC (fine needle aspiration cytology) were done. Each patient was evaluated for clinical features of benign breast disease at the first visit. Along with clinical correlation, Ultrasound of breast was carried out and for females more than 35 years of age mammography was carried out if any diagnostic dilemma present. Tablet Ormeloxifene was started at a dose of 30 mg twice a week for 1 month and follow up at 1, 3 and 6 months intervals. At each follow up visit, the patient was evaluated to look for changes in clinical features, decrease in nodularity as per Lucknow Cardiff Scale or decrease of pain as per Visual Analogue Scale. Each patient was followed up till a period of 6 months from the start of the study and responses were recorded.
Out of 100 patients, Majority of patients (50%) belonged to the age group of 31-40 years suggesting benign breast diseases are common in the age group of 31-40 years. Out of 100 patients, 50 patients had mastalgia as presenting complaint. 36 patients had nodularity while 14 patients had had both mastalgia and nodularity.
Maximum VAS Scale was observed as 6 in 10 patients in the age group of 18-25 years. Maximum VAS Scale was observed as 4 in 6 patients in the age group of 26-30 years. Maximum VAS Scale was observed as 8 in 11 patients in the age group of 31-40 years. Maximum VAS Scale was observed as 6 in 3 patients in the age group of 41-50 years. Among age group 18-25 years, 09 patients had nodularity of Grade 3. In age group 26-30 years, 11 patients had nodularity of Grade 2. Among age group 31-40 years, 27 patients had nodularity of Grade 3. In age group 41-50 years, 3 patients had nodularity of Grade 1.
43 patients had VAS ‘0’ at the end of 1 month and 10 patients had VAS ‘0’ at end of 3 months. 50 patients had grade 0 nodularity at 1 month. 10 patients had grade 0 nodularity at 3 months. 7 patients had grade 0 nodularity at 6 months.
Table 1: Effect of Ormeloxifene in benign breast diseases
|
Relief of Symptoms |
Number of Patients |
|
At the end of 1 month |
50 |
|
At the end of 3 months |
10 |
|
At the end of 6 months |
7 |
|
Not relieved after 6 months |
33 |
|
Total patients |
100 |
The symptomatic relief from Mastalgia can be comparable to study by Vinita et al with VAS Scale. Out of 100 patients, 50 patients were relieved with tablet Ormeloxifene 30 mg twice a week at the end of 1 month. Symptomatic relief from pain and nodularity by using tablet Ormeloxifene 60 mg twice a week at the end of 3 months was noted in 10 patients. Symptomatic relief from pain and nodularity by using tablet Ormeloxifene 60 mg twice a week at the end of 6 months was observed in 7 patients. Symptoms were not relieved in remaining 33 patients even with an increased dose at the end of 6 months.
Benign breast diseases are more common in the age group between 31 to 40 years. Mastalgia and nodularity are common presentations in benign breast disease. Clinical assessment of breast along with ultrasonography and FNAC is extremely useful in the diagnosis of benign breast diseases. Out of 100 patients, 50 patients were relieved with Tab Ormeloxifene 30 mg twice a week at the end of 1 month. Symptomatic relief from Pain and Nodularity by using Tablet Ormeloxifene 60 mg twice a week at the end of 3 months was noted in 10 Patients. Symptomatic relief from Pain and Nodularity by using Tablet Ormeloxifene 60 mg twice a week at the end of 6 months was observed in 7 Patients. Symptoms were not relieved in remaining 33 patients even with an increased dose at the end of 6 months. Ormeloxifene is an effective drug for treatment of breast pain and nodularity. It has significant efficacy for the treatment of benign breast diseases. Ormeloxifene can be used as first line of treatment in patients with benign breast diseases with twice weekly dose and majority of the patients show relief of their symptoms at a period of 1 month.
The authors express their sincere gratitude to the head of department for his continuous support and encouragement throughout this work.
No funding was received for this study.
The authors declare no conflicts of interest.
[1] Vinita K, Renu R. Effect of Ormeloxifene on Mastalgia and Fibrocystic breast diseases. J Med Sci Clin Res. 2019; 7:981-984.
[2] Girish TU, Mohammad F. Role of ormeloxifene in regression of benign breast diseases. Int Surg J. 2020: March;7(3):743-750.
[3] Sheetal C, Rajesh KP. An Analytical Study to Evaluate Role of Ormeloxifene in Cases of Benign Breast Diseases. Int J Pharm Clin Res 2024; 16(6); 1511-1515.
[4] Srivastava A, Mansel RE, Arvind N, Prasad K, Dhar A, Chabra A. Evidence-based management of Mastalgia: a meta-analysis of randomised trials. Breast J. 2007:16(5):503-512.
[5] Goyal A, Mansel RE. A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J. 2005:11(1):41-47.
[6] Kumar K, Pallavi K, Martand K, Mohan L, Roy SS, Prakash P, Maharshi V. Efficacy and Safety of Centchroman in the Treatment of Breast Fibroadenoma: A Systematic Review and Meta-Analysis. Cureus 2025: 17(6).
[7] Venu S, Ravi TP. Role of ormeloxifene in non-surgical management of fibroadenoma. Ind J App Res. 2020:9:67-68.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications